Whitefort Capital Management, LP

2. Key Holdings

The portfolio is dominated by a few significant positions, indicating high manager conviction in specific names.

• Arbutus Biopharma Corp (ABUS): This is the largest holding, comprising 19.45% of the portfolio ($60.58M). A position of this size in a healthcare/biotech name suggests the firm has a strong positive outlook on the company's pipeline or near-term catalysts.
• Roivant Sciences Ltd: The second-largest position at 17.15% ($53.44M). Combined with Arbutus, nearly 37% of the portfolio is tied up in just two healthcare/biotech entities, indicating a thematic tilt toward this sector.
• Genworth Financial Inc (GNW): The top non-healthcare holding represents 10.58% ($32.95M). This financial services exposure provides a diversification away from the volatile biotech sector, though it remains a large, single-stock concentration.
• SPDR S&P 500 ETF (SPY): A notable addition this quarter, SPY accounts for 8.55% ($26.65M). This serves as a liquidity buffer and provides market exposure, potentially acting as a hedge against the idiosyncratic risks of the other large single-stock positions.